|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7135465||BRISTOL MYERS SQUIBB||Sustained release beadlets containing stavudine|| |
(7 months ago)
|BRISTOL MYERS SQUIBB||Sustained release beadlets containing stavudine|| |
(a month ago)
Zerit Xr is owned by Bristol Myers Squibb.
Zerit Xr contains Stavudine.
Zerit Xr has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zerit Xr are:
Zerit Xr was authorised for market use on 31 December, 2002.
Zerit Xr is available in capsule, extended release;oral dosage forms.
Zerit Xr can be used as method for treating hiv-1 infection.
The generics of Zerit Xr are possible to be released after 18 August, 2023.
Market Authorisation Date: 31 December, 2002
Treatment: Method for treating hiv-1 infection
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic